These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 35330996)

  • 1. Co-treatment of betulin and gefitinib is effective against EGFR wild-type/KRAS-mutant non-small cell lung cancer by inducing ferroptosis.
    Yan WY; Cai J; Wang JN; Gong YS; Ding XB
    Neoplasma; 2022 May; 69(3):648-656. PubMed ID: 35330996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dihydroartemisinin enhances gefitinib cytotoxicity against lung adenocarcinoma cells by inducing ROS-dependent apoptosis and ferroptosis.
    Lai XY; Shi YM; Zhou MM
    Kaohsiung J Med Sci; 2023 Jul; 39(7):699-709. PubMed ID: 37057810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Curcumin overcome primary gefitinib resistance in non-small-cell lung cancer cells through inducing autophagy-related cell death.
    Chen P; Huang HP; Wang Y; Jin J; Long WG; Chen K; Zhao XH; Chen CG; Li J
    J Exp Clin Cancer Res; 2019 Jun; 38(1):254. PubMed ID: 31196210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gefitinib sensitization of cisplatin-resistant wild-type EGFR non-small cell lung cancer cells.
    Li A; Cao W; Liu X; Zhang Y; Ma Y; Xu R; Zhang R; Liu X; Zhou S; Wang R; Liu J; Tang X
    J Cancer Res Clin Oncol; 2020 Jul; 146(7):1737-1749. PubMed ID: 32342201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Repurposing loperamide to overcome gefitinib resistance by triggering apoptosis independent of autophagy induction in KRAS mutant NSCLC cells.
    Tong CWS; Wu MMX; Yan VW; Cho WCS; To KKW
    Cancer Treat Res Commun; 2020; 25():100229. PubMed ID: 33152554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells.
    Gong H; Li Y; Yuan Y; Li W; Zhang H; Zhang Z; Shi R; Liu M; Liu C; Chen C; Liu H; Chen J
    BMC Cancer; 2020 Dec; 20(1):1189. PubMed ID: 33276757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combinative treatment of β-elemene and cetuximab is sensitive to KRAS mutant colorectal cancer cells by inducing ferroptosis and inhibiting epithelial-mesenchymal transformation.
    Chen P; Li X; Zhang R; Liu S; Xiang Y; Zhang M; Chen X; Pan T; Yan L; Feng J; Duan T; Wang D; Chen B; Jin T; Wang W; Chen L; Huang X; Zhang W; Sun Y; Li G; Kong L; Chen X; Li Y; Yang Z; Zhang Q; Zhuo L; Sui X; Xie T
    Theranostics; 2020; 10(11):5107-5119. PubMed ID: 32308771
    [No Abstract]   [Full Text] [Related]  

  • 8. Licochalcone B inhibits growth and induces apoptosis of human non-small-cell lung cancer cells by dual targeting of EGFR and MET.
    Oh HN; Lee MH; Kim E; Yoon G; Chae JI; Shim JH
    Phytomedicine; 2019 Oct; 63():153014. PubMed ID: 31323446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atorvastatin overcomes gefitinib resistance in KRAS mutant human non-small cell lung carcinoma cells.
    Chen J; Bi H; Hou J; Zhang X; Zhang C; Yue L; Wen X; Liu D; Shi H; Yuan J; Liu J; Liu B
    Cell Death Dis; 2013 Sep; 4(9):e814. PubMed ID: 24071646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PCK2 induces gefitinib resistance by suppresses ferroptosis in non-small cell lung cancer.
    Yan T; Zhang N; Liu F; Wang H; Zhang J; Jin X; Jiang S
    Biochem Biophys Res Commun; 2024 Sep; 723():150200. PubMed ID: 38850814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Panobinostat sensitizes KRAS-mutant non-small-cell lung cancer to gefitinib by targeting TAZ.
    Lee WY; Chen PC; Wu WS; Wu HC; Lan CH; Huang YH; Cheng CH; Chen KC; Lin CW
    Int J Cancer; 2017 Nov; 141(9):1921-1931. PubMed ID: 28710768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined treatment with N-acetylcysteine and gefitinib overcomes drug resistance to gefitinib in NSCLC cell line.
    Li J; Wang XH; Hu J; Shi M; Zhang L; Chen H
    Cancer Med; 2020 Feb; 9(4):1495-1502. PubMed ID: 31891230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lovastatin overcomes gefitinib resistance in human non-small cell lung cancer cells with K-Ras mutations.
    Park IH; Kim JY; Jung JI; Han JY
    Invest New Drugs; 2010 Dec; 28(6):791-9. PubMed ID: 19760159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cigarette Smoke Induces Gefitinib Resistance in NSCLC Cells 
via ROS/Sirt3/SOD2 Pathway].
    Zi Y; Liao K; Chen H
    Zhongguo Fei Ai Za Zhi; 2023 Apr; 26(4):245-256. PubMed ID: 37183639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of Combined Use of Everolimus and Second-Generation Pan-EGRF Inhibitors in
    da Silva-Oliveira RJ; Gomes INF; da Silva LS; Lengert AVH; Laus AC; Melendez ME; Munari CC; Cury FP; Longato GB; Reis RM
    Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Curcumin induces EGFR degradation in lung adenocarcinoma and modulates p38 activation in intestine: the versatile adjuvant for gefitinib therapy.
    Lee JY; Lee YM; Chang GC; Yu SL; Hsieh WY; Chen JJ; Chen HW; Yang PC
    PLoS One; 2011; 6(8):e23756. PubMed ID: 21858220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TRIP13 overexpression promotes gefitinib resistance in non‑small cell lung cancer via regulating autophagy and phosphorylation of the EGFR signaling pathway.
    Xiao Z; Li M; Zhang X; Rong X; Xu H
    Oncol Rep; 2023 May; 49(5):. PubMed ID: 36896765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AT-101 enhances gefitinib sensitivity in non-small cell lung cancer with EGFR T790M mutations.
    Zhao R; Zhou S; Xia B; Zhang CY; Hai P; Zhe H; Wang YY
    BMC Cancer; 2016 Jul; 16():491. PubMed ID: 27431492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TAZ sensitizes EGFR wild-type non-small-cell lung cancer to gefitinib by promoting amphiregulin transcription.
    Yuan W; Xu W; Li Y; Jiang W; Li Y; Huang Q; Chen B; Wu S; Wang Y; Song W; Zhao W; Wu J
    Cell Death Dis; 2019 Mar; 10(4):283. PubMed ID: 30911072
    [TBL] [Abstract][Full Text] [Related]  

  • 20. STAT3 inhibitor BBI608 enhances the antitumor effect of gefitinib on EGFR-mutated non-small cell lung cancer cells.
    Wang Q; Lu B; Zhang Y; Yu J; Guo J; Zhou Q; Lv H; Sun Y
    Hum Cell; 2021 Nov; 34(6):1855-1865. PubMed ID: 34370268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.